Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Kadcyla

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EU Backs AstraZeneca-Daiichi’s Enhertu for Breast Cancer
    EU Backs AstraZeneca-Daiichi’s Enhertu for Breast Cancer

    01 Mar 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/eu-backs-astrazeneca-daiichis-enhertu-breast-cancer-treatment-post-endocrine-2025-02-28/#:~:text=Feb%2028%20(Reuters)%20%2D%20The,suitable%20for%20additional%20hormone%20treatments.

    REUTERS
    01 Mar 2025
    Share Share
    Genentech's Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.
    Genentech's Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.

    02 Feb 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427

    FDA
    02 Feb 2022
    Share Share
    PhaseBio Names Jonathan Birchall as Chief Commercial Officer
    PhaseBio Names Jonathan Birchall as Chief Commercial Officer

    18 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211118006306/en

    BUSINESSWIRE
    18 Nov 2021
    Share Share
    Seagen undaunted by AstraZeneca-Daiichi's Enhertu
    Seagen undaunted by AstraZeneca-Daiichi's Enhertu

    30 Oct 2021

    // K. Dunleavy FIERCEPHARMA

    https://endpts.com/an-allergan-psychiatric-drug-failed-late-stage-depression-studies-but-abbvie-is-going-for-approval-anyway/

    K. Dunleavy FIERCEPHARMA
    30 Oct 2021
    Share Share
    AstraZeneca's Enhertu gets BTD for breast cancer; Centessa nabs $300M loan
    AstraZeneca's Enhertu gets BTD for breast cancer; Centessa nabs $300M loan

    05 Oct 2021

    // P. Schloesser ENDPTS

    https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/

    P. Schloesser ENDPTS
    05 Oct 2021
    Share Share
    Canada's Xenon touts win for its daily epilepsy pill
    Canada's Xenon touts win for its daily epilepsy pill

    05 Oct 2021

    // P. Schloesser ENDPTS

    https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/

    P. Schloesser ENDPTS
    05 Oct 2021
    Share Share